Angiomyolipoma reductions 50 % in the sum of volumes of all target lesions were seen only in everolimus-treated patients ( 56.5 , 78.3 and 80.0 % ) compared with placebo-treated patients ( 0 % at each time point ) at Weeks 12 , 24 and 48 , respectively .